InterVenn

InterVenn, established in 2017, is at the forefront of glycoproteomics with its innovative GlycoVision™ platform. This platform significantly improves the speed, scope, and scale of glycoproteomic studies, enabling new insights into biomarker discovery, disease detection and progression, therapeutic response, and monitoring. GlycoVision™ is the first commercially available glycoproteomic platform designed for early disease detection, response prediction, disease prognosis, and therapeutic monitoring, detecting approximately 700 of the most highly abundant glycoisoforms found in blood.

InterVenn’s AI-driven platform unlocks the glycoproteome with unparalleled detail, utilizing liquid chromatography-tandem mass spectrometry (LC-MS/MS) for comprehensive glycoproteomic analysis. Their AI platform rapidly annotates chromatograms with over 99% concordance to expert analyses, translating LC-MS data into quantitative biomarker data through the Peak Integration Platform (PIP). This technology focuses on signal processing and expanding the capabilities of mass spectrometry, allowing the identification and quantification of a wide range of glycopeptides and their glycan structures.

One of InterVenn’s notable products is GlycoKnow™ Colon, a blood-based laboratory-developed test for the early detection of colorectal cancer. This test assesses the presence of adenomas with high-grade dysplasia or colorectal cancer, relying on the host immune system rather than tumor-produced biomarkers for early disease detection.

InterVenn’s glycoproteomic studies have identified specific glycan structures associated with various diseases, including cancer, infectious diseases, neurodegenerative diseases, and inflammatory diseases. Their clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), ensuring high standards in their testing processes. Additionally, InterVenn has created a knowledge graph combining glycoproteomic data with public datasets to provide unique insights into disease-related pathways, further advancing the field of glycoproteomics.